# EDGAR Filing Document

**Accession Number:** 0001477845
**File Stem:** 0001104659-25-094016
**Filing Date:** 2025-9
**Character Count:** 3254
**Document Hash:** 0319f6d5bf9b80c99d26079f61c5b268
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-094016.hdr.sgml**: 20260224

**ACCESSION NUMBER**: 0001104659-25-094016

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250929

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Annovis Bio, Inc.
- **CENTRAL INDEX KEY:** 0001477845
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 262540421
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 101 LINDENWOOD DRIVE, SUITE 225
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355
- **BUSINESS PHONE:** 484-875-3192

**MAIL ADDRESS:**
- **STREET 1:** 101 LINDENWOOD DRIVE, SUITE 225
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** QR Pharma, Inc.
- **DATE OF NAME CHANGE:** 20091202

Via EDGAR

September 19, 2025

Ms. Jenn Do and Ms. Vanessa Robertson<br> U.S. Securities & Exchange Commission <br> Division of Corporation Finance <br> Office of Life Sciences<br> 100 F Street, NE<br> Washington, D.C. 20549

Re: Annovis Bio, Inc.<br> Form 10-K for the fiscal year ended December 31, 2024<br> Filed March 21, 2025<br> File No. 001-39202

Dear Ms. Do and Ms. Robertson:

Annovis Bio, Inc. (the "Company") is in receipt of the Staff's letter dated September 4, 2025 (the "Staff's Letter") regarding the Company's Annual Report on Form 10-K (the "Form 10-K"). In the letter the Staff requested that the Company provide a breakdown of the Alzheimer's and Parkinson's studies. Our 2024 10-K states that the company "tracks and records information regarding external research and development expenses for each study or trial that we conduct." This is an inaccurate statement as it pertains to the breakout of Alzheimer's and Parkinson's studies and was meant to say that we are tracking clinical as well as manufacturing, pre-clinical, and research expenses.

The Company hereby agrees that, beginning with the 3rd quarter of 2025, we will track Alzheimer 's and Parkinson's expenses separately. We will provide narrative disclosure on a going-forward basis only (no prior period comparison) regarding the breakdown of research and development expenses between the Alzheimer's study and the Parkinson's study. In addition, the filings will continue to show the breakdown as reported in previous filings, Exhibit A. We will provide comparative analysis of the clinical study expenses when the information becomes available.

Please contact me at (610) 880-8485 or by email at maccecchini@annovisbio.com if you have any additional questions.

Sincerely,

![](tm2527170d2_correspimg001.jpg)

Maria Maccecchini

President and Chief Executive Officer

**EXHIBIT A**

**R&D Expenses for the quarters ended**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **1/1/2024 -<br> 12/31/2024** | **1/1/2024-<br> 3/31/2025** | **4/1/2025-<br> 6/30/2025** | **1/1/2025-<br> 6/30/2025** |
| Clinical (AD & PD) | 16238273 | 4072968 | 4249437 | 8322405 |
| CMC | 2589833 | 713132 | 681885 | 1395017 |
| Preclinical | 1167341 | 225416 | 230600 | 456016 |
|  | 19995447 | 5011517 | 5161921 | 10173438 |

---